Combination of metformin and gefitinib as first-line therapy for nondiabetic advanced NSCLC patients with EGFR mutations: a randomized, double-blind phase II trial
L Li, L Jiang, Y Wang, Y Zhao, XJ Zhang, G Wu… - Clinical Cancer …, 2019 - AACR
L Li, L Jiang, Y Wang, Y Zhao, XJ Zhang, G Wu, X Zhou, J Sun, J Bai, B Ren, K Tian, Z Xu…
Clinical Cancer Research, 2019•AACRPurpose: Preclinical and retrospective studies suggested a role for metformin in sensitizing
patients who have diabetes with non–small cell lung cancer (NSCLC) to EGFR tyrosine
kinase inhibitors (TKIs). We therefore examined its effects in combination with gefitinib in
patients without diabetes harboring EGFR mutations (EGFRm). Patients and Methods: A
total of 224 patients without diabetes with treatment-naïve stage IIIB–IV EGFRm NSCLC
were randomly assigned in a 1: 1 ratio to receive gefitinib plus either metformin or placebo …
patients who have diabetes with non–small cell lung cancer (NSCLC) to EGFR tyrosine
kinase inhibitors (TKIs). We therefore examined its effects in combination with gefitinib in
patients without diabetes harboring EGFR mutations (EGFRm). Patients and Methods: A
total of 224 patients without diabetes with treatment-naïve stage IIIB–IV EGFRm NSCLC
were randomly assigned in a 1: 1 ratio to receive gefitinib plus either metformin or placebo …
Purpose
Preclinical and retrospective studies suggested a role for metformin in sensitizing patients who have diabetes with non–small cell lung cancer (NSCLC) to EGFR tyrosine kinase inhibitors (TKIs). We therefore examined its effects in combination with gefitinib in patients without diabetes harboring EGFR mutations (EGFRm).
Patients and Methods
A total of 224 patients without diabetes with treatment-naïve stage IIIB–IV EGFRm NSCLC were randomly assigned in a 1:1 ratio to receive gefitinib plus either metformin or placebo. The primary endpoint was progression-free survival (PFS) rate at 1 year and secondary endpoints included overall survival (OS), PFS, objective response rate (ORR), and safety. Serum levels of IL6 were also examined in an exploratory analysis.
Results
The median duration of follow-up was 19.15 months. The estimated 1-year PFS rates were 41.2% [95% confidence interval (CI), 30.0–52.2] with gefitinib plus metformin and 42.9% (95% CI, 32.6–52.7) with gefitinib plus placebo (P = 0.6268). Median PFS (10.3 months vs. 11.4 months) and median OS (22.0 months vs. 27.5 months) were numerically lower in the metformin group, while ORRs were similar between the two arms (66% vs. 66.7%). No significant treatment group differences were detected across all subgroups with respect to PFS, including those with elevated levels of IL6. Metformin combined with gefitinib resulted in a remarkably higher incidence of diarrhea compared with the control arm (78.38% vs. 43.24%).
Conclusions
Our study showed that addition of metformin resulted in nonsignificantly worse outcomes and increased toxicity and hence does not support its concurrent use with first-line EGFR-TKI therapy in patients without diabetes with EGFRm NSCLC.
AACR
